I-Corps: Large Microfluidic Bioreactor for Bio-molecule Manufacturing

I-Corps：用于生物分子制造的大型微流体生物反应器

• 批准号: 2018107
• 负责人: Aparna Aravelli
• 金额: $ 5万
• 依托单位: Florida International University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2021-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2018107&HistoricalAwards=false
• 关键词: Corps; Large; Microfluidic; Bioreactor; Bio

The broader impact/commercial potential of this I-Corps project would be to reduce the cost of production of biologics by an order of magnitude through a novel bioreactor. Such a platform has the potential to reduce barriers to biologics-based treatments, through reduced costs of manufacture. It will also improve therapeutic effectiveness by providing high quality, personalized, and cost-effective production of bio-drugs. This reduced cost of manufacturing would help bring biologics for rare diseases to market. This I-Corps Project leverages fine spatiotemporal control over the cellular microenvironment for controlled mass and heat transfer and fluid dynamics to optimize the production of the target biomolecules and improve manufacturing of biologics for personalized medicine. The proposed solution is a Big Microfluid (BM) bioreactor.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

I-Corps项目的更广泛影响/商业潜力将是通过一种新型生物反应器将生物制剂的生产成本降低一个数量级。通过降低制造成本，这种平台有可能减少基于生物制剂的治疗的障碍。它还将通过提供高质量、个性化和具有成本效益的生物药物生产来提高治疗效果。生产成本的降低将有助于将治疗罕见疾病的生物制剂推向市场。这个I-Corps项目利用对细胞微环境的精细时空控制来控制质量和传热以及流体动力学，以优化目标生物分子的生产，并改善用于个性化医疗的生物制剂的生产。提出的解决方案是一个大微流体（BM）生物反应器。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。